Tumour necrosis factor (TNF) receptor family in GtoPdb v.2023.1

David MacEwan

1. University of Liverpool, UK

Abstract

Dysregulated TNFR signalling is associated with many inflammatory disorders, including some forms of arthritis and inflammatory bowel disease, and targeting TNF has been an effective therapeutic strategy in these diseases and for cancer immunotherapy [5, 6, 49].

Contents

This is a citation summary for Tumour necrosis factor (TNF) receptor family in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [8].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

Tumour necrosis factor (TNF) receptor family
https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=334

Introduction to Tumour necrosis factor (TNF) receptor family
https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=334

Receptors

TNFR1(tumor necrosis factor receptor 1)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870

TNFR2(tumor necrosis factor receptor 2)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1871

lymphotoxin β receptor
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1872

OX40
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1873

CD40
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874
Fas
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1875
decoy receptor 3
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2322
CD27
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1876
CD30
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1877
4-1BB
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1878
DR4 (death receptor 4)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1879
DR5 (death receptor 5)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1880
decoy receptor 1
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2323
decoy receptor 2
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2324
RANK (receptor activator of NF-kappa B)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1881
OPG (osteoprotegerin)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1882
DR3 (death receptor 3)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1883
TWEAK receptor
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1884
TACI
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1885
BAFF-R (BAFF receptor)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1886
HVEM (herpes virus entry mediator)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1887
nerve growth factor receptor
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888
BCMA (B cell maturation antigen)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1889
GITR (glucocorticoid-induced TNF receptor)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1890
TAJ (toxicity and JNK inducer)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1891
RELT
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1892
DR6 (death receptor 6)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1893
TNFRSF22
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1894
TNFRSF23
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1895
ectodysplasin A2 isoform receptor
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1896
ectodysplasin 1, anhidrotic receptor
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2325

References


